Since starting the ACR on Air podcast in 2019, Mohammad Ursani, MD, FACP, RhMSUS, has become chair of the Committee on Communications and Marketing. Here, he shares some plans for the ACR website, podcast and more.
COVID-19 vaccination, treatments for rheumatic disease and more—the Late-Breaking Abstracts session of ACR Convergence 2021 highlighted six studies with implications for rheumatology.
The differences between axial spondyloarthropathy (axSpA) and axial involvement in psoriatic arthritis (axPsA) have clinical and therapeutic implications. Three experts discussed the distinctions during ACR Convergence 2021.
The use of guselkumab improved joint and skin symptoms in biologic naive patients with PsA, according to research presented during ACR Convergence 2021.
The FDA has approved the use of secukinumab for pediatric patients with enthesitis-related arthritis and psoriatic arthritis, after research showed a longer time to disease flare than placebo.
Melissa Griffith, MD, discussed the diagnosis and treatment of interstitial lung disease (ILD) in patients with rheumatic diseases, including connective tissue disease and more.
At an ACR COVID-19 town hall on COVID-19, infectious disease experts discussed the most up-to-datecurrent information on pre- and post-exposure monoclonal antibody therapy, oral antivirals and vaccines for rheumatology patients.
In 2022, rheumatology practices should prepare for documentation, coding, billing and reimbursement revisions related to evaluation and management (E/M), split/shared billing policies and telehealth services.